Gemfibrozil

Administration
  • Type: Antihyperlipidemic
  • Dosage Forms: Tablet, 600mg
  • Routes of Administration: oral
  • Common Trade Names: Lopid

Adult Dosing
  • 600mg PO BID 30m before meals

Pediatric Dosing
  • Safety/efficacy not established

Special Populations
  • Pregnancy Rating: C
  • Lactation risk: Infant risk cannot be ruled out
  • Renal dosing: not recommended in severe renal impairment
  • Hepatic dosing: contraindicated in hepatic dysfunction

Contraindications
  • Allergy to class/drug
  • Concomitant dasabuvir, repaglinide, or simvastatin
  • Hepatic dysfunction, primary biliary cirrhosis, preexisting gallbladder disease
  • Severe renal impairment

Adverse Reactions

Serious
  • Increased LFTs
  • Rhabdomyolysis
  • Atrial Fibrillation

Common
  • Abdominal pain, indigestion
  • Appendicitis
  • Fatigue, Vertigo
  • Rash

Pharmacology
  • Half-life: 1.5h
  • Metabolism: Hepatic. Inhibitor of CYP2C8, OATP1B1, and OAT3, substrate of UGT2B7
  • Excretion: Mostly renal

Mechanism of Action
  • Stimulates peroxisome proliferator activated receptor alpha, which causes a decrease in triglyceride levels and an increase in high-density lipoprotein levels

Comments


See Also

References
    This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.